The influence of age on the association between cholesterol and cognitive function

Experimental Gerontology

Volumn 44, Issue 1-2, 2009, Pages 112-122

  van Vliet, Peter ^a   van de Water, Willemien ^a   de Craen, Anton J M ^a   Westendorp, Rudi G J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Age; Cholesterol; Cognition; Dementia; Statins

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

AGING; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COGNITION; COGNITIVE DEFECT; DEMENTIA; HUMAN; HYPERCHOLESTEROLEMIA; MORTALITY; PRIORITY JOURNAL;

AGE FACTORS; AGED; AGING; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; COGNITION; COGNITION DISORDERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; RISK; TREATMENT OUTCOME;

EID: 57349085740     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2008.05.004     Document Type: Article

References (108)

1. Abbott R.D., Sharp D.S., Burchfiel C.M., Curb J.D., Rodriguez B.L., Hakim A.A., and Yano K. Cross-sectional and longitudinal changes in total and high-density-lipoprotein cholesterol levels over a 20-year period in elderly men: the Honolulu Heart Program. Ann. Epidemiol. 7 6 (1997) 417-424
2. Acanfora D., Trojano L., Iannuzzi G.L., Furgi G., Picone C., Rengo C., Abete P., and Rengo F. The brain in congestive heart failure. Arch. Gerontol. Geriatr. 23 3 (1996) 247-256
3. Anderson K.M., Castelli W.P., and Levy D. Cholesterol and mortality 30 years of follow-up from the Framingham study. JAMA 257 16 (1987) 2176-2180
4. Aronson M.K., Ooi W.L., Morgenstern H., Hafner A., Masur D., Crystal H., Frishman W.H., Fisher D., and Katzman R. Women, myocardial infarction, and dementia in the very old. Neurology 40 7 (1990) 1102-1106
5. Arvanitakis Z., Schneider J.A., Wilson R.S., Bienias J.L., Kelly J.F., Evans D.A., and Bennett D.A. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70 19 (2008) 1795-1802
6. Asia Pacific Cohort Studies Collaboration, 2007. Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region. Diabetologia 50 (11), 2289-2297.
7. Atzmon G., Gabriely I., Greiner W., Davidson D., Schechter C., and Barzilai N. Plasma HDL levels highly correlate with cognitive function in exceptional longevity. J. Gerontol. A Biol. Sci. Med. Sci. 57 11 (2002) M712-M715
8. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., Kastelein J.J., Bittner V., and Fruchart J.C. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357 13 (2007) 1301-1310
9. Benfante R., and Reed D. Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly?. JAMA 263 3 (1990) 393-396
10. Berry J.D., Dyer A., Carnethon M., Tian L., Greenland P., and Lloyd-Jones D.M. Association of traditional risk factors with cardiovascular death across 0 to 10, 10 to 20, and >20 years follow-up in men and women. Am. J. Cardiol. 101 1 (2008) 89-94
11. Blennow K., de Leon M.J., and Zetterberg H. Alzheimer's disease. Lancet 368 9533 (2006) 387-403
12. Bonarek M., Barberger-Gateau P., Letenneur L., Deschamps V., Iron A., Dubroca B., and Dartigues J.F. Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology 19 3 (2000) 141-148
13. Brescianini S., Maggi S., Farchi G., Mariotti S., Di Carlo A., Baldereschi M., and Inzitari D. Low total cholesterol and increased risk of dying: are low levels clinical warning signs in the elderly? Results from the Italian Longitudinal Study on Aging. J. Am. Geriatr. Soc. 51 7 (2003) 991-996
14. Breteler M.M., Claus J.J., Grobbee D.E., and Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ 308 6944 (1994) 1604-1608
15. Bursi F., Rocca W.A., Killian J.M., Weston S.A., Knopman D.S., Jacobsen S.J., and Roger V.L. Heart disease and dementia: a population-based study. Am. J. Epidemiol. 163 2 (2006) 135-141
16. Cacciatore F., Abete P., Ferrara N., Calabrese C., Napoli C., Maggi S., Varricchio M., and Rengo F. Congestive heart failure and cognitive impairment in an older population. Osservatorio Geriatrico Campano Study Group. J. Am. Geriatr. Soc. 46 11 (1998) 1343-1348
17. Castelli W.P., Anderson K., Wilson P.W., and Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann. Epidemiol. 2 1-2 (1992) 23-28
18. Castelli W.P., Wilson P.W., Levy D., and Anderson K. Cardiovascular risk factors in the elderly. Am. J. Cardiol. 63 16 (1989) 12H-19H
19. Corti M.C., Guralnik J.M., Salive M.E., Harris T., Ferrucci L., Glynn R.J., and Havlik R.J. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann. Intern. Med. 126 10 (1997) 753-760
20. Corti M.C., Guralnik J.M., Salive M.E., Harris T., Field T.S., Wallace R.B., Berkman L.F., Seeman T.E., Glynn R.J., and Hennekens C.H. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 274 7 (1995) 539-544
21. de la Torre J.C. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33 4 (2002) 1152-1162
22. De Ronchi D., Palmer K., Pioggiosi P., Atti A.R., Berardi D., Ferrari B., Dalmonte E., and Fratiglioni L. The combined effect of age, education, and stroke on dementia and cognitive impairment no dementia in the elderly. Dement. Geriatr. Cogn. Disord. 24 4 (2007) 266-273
23. Dietschy J.M., and Turley S.D. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12 2 (2001) 105-112
24. Dufouil C., Richard F., Fievet N., Dartigues J.F., Ritchie K., Tzourio C., Amouyel P., and Alperovitch A. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 64 9 (2005) 1531-1538
25. Elias M.F., Sullivan L.M., Elias P.K., Vasan R.S., D'Agostino Sr. R.B., Seshadri S., Au R., Wolf P.A., and Benjamin E.J. Atrial fibrillation is associated with lower cognitive performance in the Framingham offspring men. J. Stroke Cerebrovasc. Dis. 15 5 (2006) 214-222
26. Elwood P.C., Pickering J., Bayer A., and Gallacher J.E. Vascular disease and cognitive function in older men in the Caerphilly cohort. Age Ageing 31 1 (2002) 43-48
27. Evans R.M., Emsley C.L., Gao S., Sahota A., Hall K.S., Farlow M.R., and Hendrie H. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 54 1 (2000) 240-242
28. Fagan A.M., Younkin L.H., Morris J.C., Fryer J.D., Cole T.G., Younkin S.G., and Holtzman D.M. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann. Neurol. 48 2 (2000) 201-210
29. Fassbender K., Stroick M., Bertsch T., Ragoschke A., Kuehl S., Walter S., Walter J., Brechtel K., Muehlhauser F., von Bergmann K., and Lutjohann D. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 59 8 (2002) 1257-1258
30. Ferrara A., Barrett-Connor E., and Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Circulation 96 1 (1997) 37-43
31. Goldbourt U., Holtzman E., and Neufeld H.N. Total and high density lipoprotein cholesterol in the serum and risk of mortality: evidence of a threshold effect. Br. Med. J. (Clin. Res. Ed.) 290 6477 (1985) 1239-1243
32. Goldbourt U., Yaari S., and Medalie J.H. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler. Thromb. Vasc. Biol. 17 1 (1997) 107-113
33. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs Jr. D.R., Bangdiwala S., and Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 1 (1989) 8-15
34. Haan M.N., Shemanski L., Jagust W.J., Manolio T.A., and Kuller L. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 282 1 (1999) 40-46
35. Hajjar I., Schumpert J., Hirth V., Wieland D., and Eleazer G.P. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J. Gerontol. A Biol. Sci. Med. Sci. 57 7 (2002) M414-M418
36. Hall K., Murrell J., Ogunniyi A., Deeg M., Baiyewu O., Gao S., Gureje O., Dickens J., Evans R., Smith-Gamble V., Unverzagt F.W., Shen J., and Hendrie H. Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology 66 2 (2006) 223-227
37. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352 16 (2005) 1685-1695
38. Heart Protection Study Collaborative Group, 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (9326), 7-22.
39. Henderson V.W., Guthrie J.R., and Dennerstein L. Serum lipids and memory in a population based cohort of middle age women. J. Neurol. Neurosurg. Psychiatry 74 11 (2003) 1530-1535
40. Hofman A., Ott A., Breteler M.M., Bots M.L., Slooter A.J., van Harskamp F., van Duijn C.N., Van Broeckhoven C., and Grobbee D.E. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349 9046 (1997) 151-154
41. Jacobs Jr. D.R., Mebane I.L., Bangdiwala S.I., Criqui M.H., and Tyroler H.A. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am. J. Epidemiol. 131 1 (1990) 32-47
42. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 9242 (2000) 1627-1631
43. Jorm A.F., and Jolley D. The incidence of dementia: a meta-analysis. Neurology 51 3 (1998) 728-733
44. Kivipelto M., Helkala E.L., Hanninen T., Laakso M.P., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., and Nissinen A. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 56 12 (2001) 1683-1689
45. Kivipelto M., Helkala E.L., Laakso M.P., Hanninen T., Hallikainen M., Alhainen K., Iivonen S., Mannermaa A., Tuomilehto J., Nissinen A., and Soininen H. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann. Intern. Med. 137 3 (2002) 149-155
46. Kivipelto M., Helkala E.L., Laakso M.P., Hanninen T., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., and Nissinen A. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322 7300 (2001) 1447-1451
47. Kivipelto M., Ngandu T., Fratiglioni L., Viitanen M., Kareholt I., Winblad B., Helkala E.L., Tuomilehto J., Soininen H., and Nissinen A. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch. Neurol. 62 10 (2005) 1556-1560
48. Klag M.J., Ford D.E., Mead L.A., He J., Whelton P.K., Liang K.Y., and Levine D.M. Serum cholesterol in young men and subsequent cardiovascular disease. N. Engl. J. Med. 328 5 (1993) 313-318
49. Knopman D.S., Petersen R.C., Cha R.H., Edland S.D., and Rocca W.A. Coronary artery bypass grafting is not a risk factor for dementia or Alzheimer disease. Neurology 65 7 (2005) 986-990
50. Kronmal R.A., Cain K.C., Ye Z., and Omenn G.S. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch. Intern. Med. 153 9 (1993) 1065-1073
51. Kronzon I., and Tunick P.A. Aortic atherosclerotic disease and stroke. Circulation 114 1 (2006) 63-75
52. Krumholz H.M., Seeman T.E., Merrill S.S., Mendes de Leon C.F., Vaccarino V., Silverman D.I., Tsukahara R., Ostfeld A.M., and Berkman L.F. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 272 17 (1994) 1335-1340
53. Kuo Y.M., Emmerling M.R., Bisgaier C.L., Essenburg A.D., Lampert H.C., Drumm D., and Roher A.E. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem. Biophys. Res. Commun. 252 3 (1998) 711-715
54. Kuusisto J., Koivisto K., Mykkanen L., Helkala E.L., Vanhanen M., Hanninen T., Kervinen K., Kesaniemi Y.A., Riekkinen P.J., and Laakso M. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 315 7115 (1997) 1045-1049
55. Launer L.J., White L.R., Petrovitch H., Ross G.W., and Curb J.D. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 57 8 (2001) 1447-1452
56. Li G., Higdon R., Kukull W.A., Peskind E., Van Valen M.K., Tsuang D., van Belle G., McCormick W., Bowen J.D., Teri L., Schellenberg G.D., and Larson E.B. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63 9 (2004) 1624-1628
57. Li G., Shofer J.B., Kukull W.A., Peskind E.R., Tsuang D.W., Breitner J.C., McCormick W., Bowen J.D., Teri L., Schellenberg G.D., and Larson E.B. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 65 7 (2005) 1045-1050
58. Lobo A., Launer L.J., Fratiglioni L., Andersen K., Di Carlo A., Breteler M.M., Copeland J.R., Dartigues J.F., Jagger C., Martinez-Lage J., Soininen H., and Hofman A. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54 11 Suppl 5 (2000) S4-S9
59. Luchsinger J.A., Reitz C., Honig L.S., Tang M.X., Shea S., and Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65 4 (2005) 545-551
60. Mariotti S., Capocaccia R., Farchi G., Menotti A., Verdecchia A., and Keys A. Age, period, cohort and geographical area effects on the relationship between risk factors and coronary heart disease mortality. 15-year follow-up of the European cohorts of the Seven Countries study. J. Chronic Dis. 39 3 (1986) 229-242
61. Mauch D.H., Nagler K., Schumacher S., Goritz C., Muller E.C., Otto A., and Pfrieger F.W. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294 5545 (2001) 1354-1357
62. Merched A., Xia Y., Visvikis S., Serot J.M., and Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol. Aging 21 1 (2000) 27-30
63. Mielke M.M., Zandi P.P., Sjogren M., Gustafson D., Ostling S., Steen B., and Skoog I. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 64 10 (2005) 1689-1695
64. Neaton J.D., and Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch. Intern. Med. 152 1 (1992) 56-64
65. Neuropathology Group. MRC CFAS, 2001. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357 (9251), 169-175.
66. Notkola I.L., Sulkava R., Pekkanen J., Erkinjuntti T., Ehnholm C., Kivinen P., Tuomilehto J., and Nissinen A. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17 1 (1998) 14-20
67. Okamura N., Arai H., Maruyama M., Matsui T., Tanji H., Sasaki H., Yoshida H., and Sugita M. Serum cholesterol and cerebrospinal fluid amyloid beta protein in Alzheimer's disease. J. Am. Geriatr. Soc. 49 12 (2001) 1738-1739
68. Ott A., Breteler M.M., de Bruyne M.C., van Harskamp F., Grobbee D.E., and Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 28 2 (1997) 316-321
69. Parale G.P., Baheti N.N., Kulkarni P.M., and Panchal N.V. Effects of atorvastatin on higher functions. Eur. J. Clin. Pharmacol. 62 4 (2006) 259-265
70. Petrovitch H., White L., Masaki K.H., Ross G.W., Abbott R.D., Rodriguez B.L., Lu G., Burchfiel C.M., Blanchette P.L., and Curb J.D. Influence of myocardial infarction, coronary artery bypass surgery, and stroke on cognitive impairment in late life. Am. J. Cardiol. 81 8 (1998) 1017-1021
71. Poehlman E.T., and Dvorak R.V. Energy expenditure, energy intake, and weight loss in Alzheimer disease. Am. J. Clin. Nutr. 71 2 (2000) 650S-655S
72. Prins N.D., van Dijk E.J., den Heijer T., Vermeer S.E., Koudstaal P.J., Oudkerk M., Hofman A., and Breteler M.M. Cerebral white matter lesions and the risk of dementia. Arch. Neurol. 61 10 (2004) 1531-1534
73. Qiu C., Winblad B., and Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 4 8 (2005) 487-499
74. Qiu C., Winblad B., Marengoni A., Klarin I., Fastbom J., and Fratiglioni L. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch. Intern. Med. 166 9 (2006) 1003-1008
75. Rea T.D., Breitner J.C., Psaty B.M., Fitzpatrick A.L., Lopez O.L., Newman A.B., Hazzard W.R., Zandi P.P., Burke G.L., Lyketsos C.G., Bernick C., and Kuller L.H. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch. Neurol. 62 7 (2005) 1047-1051
76. Reitz C., Luchsinger J., Tang M.X., Manly J., and Mayeux R. Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Neurology 64 8 (2005) 1378-1383
77. Reitz C., Tang M.X., Luchsinger J., and Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch. Neurol. 61 5 (2004) 705-714
78. Reitz C., Tang M.X., Manly J., Schupf N., Mayeux R., and Luchsinger J.A. Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 25 3 (2008) 232-237
79. Rockwood K., Howlett S., Fisk J., Darvesh S., Tuokko H., Hogan D.B., Wolfson C., and McDowell I. Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status. Neuroepidemiology 29 3-4 (2007) 201-207
80. Rockwood K., Kirkland S., Hogan D.B., MacKnight C., Merry H., Verreault R., Wolfson C., and McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59 2 (2002) 223-227
81. Roher A.E., Esh C., Kokjohn T.A., Kalback W., Luehrs D.C., Seward J.D., Sue L.I., and Beach T.G. Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler. Thromb. Vasc. Biol. 23 11 (2003) 2055-2062
82. Romas S.N., Tang M.X., Berglund L., and Mayeux R. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 53 3 (1999) 517-521
83. Rubin S.M., Sidney S., Black D.M., Browner W.S., Hulley S.B., and Cummings S.R. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann. Intern. Med. 113 12 (1990) 916-920
84. Schupf N., Costa R., Luchsinger J., Tang M.X., Lee J.H., and Mayeux R. Relationship between plasma lipids and all-cause mortality in nondemented elderly. J. Am. Geriatr. Soc. 53 2 (2005) 219-226
85. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., Kamper A.M., MacFarlane P.W., Meinders A.E., Norrie J., Packard C.J., Perry I.J., Stott D.J., Sweeney B.J., Twomey C., and Westendorp R.G. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 9346 (2002) 1623-1630
86. Simons L.A., Simons J., Friedlander Y., and McCallum J. Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis 159 1 (2001) 201-208
87. Smith G.D., Shipley M.J., Marmot M.G., and Rose G. Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA 267 1 (1992) 70-76
88. Snowdon D.A., Greiner L.H., Mortimer J.A., Riley K.P., Greiner P.A., and Markesbery W.R. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277 10 (1997) 813-817
89. Solomon A., Kareholt I., Ngandu T., Winblad B., Nissinen A., Tuomilehto J., Soininen H., and Kivipelto M. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 68 10 (2007) 751-756
90. Solomon, A., Kareholt, I., Ngandu, T., Wolozin, B., Macdonald, S.W., Winblad, B., Nissinen, A., Tuomilehto, J., Soininen, H., Kivipelto, M., 2007b. Serum total cholesterol, statins and cognition in non-demented elderly. Neurobiol. Aging, Nov. 15 [Epub ahead of print].
91. Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L.J., Browne P., Wasser D., Johnson-Traver S., Lochhead J., and Ziolwolski C. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch. Neurol. 62 5 (2005) 753-757
92. Sparks D.L., Scheff S.W., Hunsaker III J.C., Liu H., Landers T., and Gross D.R. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126 1 (1994) 88-94
93. Spilt A., Weverling-Rijnsburger A.W., Middelkoop H.A., Der Flier W.M., Gussekloo J., de Craen A.J., Bollen E.L., Blauw G.J., Van Buchem M.A., and Westendorp R.G. Late-onset dementia: structural brain damage and total cerebral blood flow. Radiology 236 3 (2005) 990-995
94. Stamler J., Wentworth D., and Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screeners of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256 20 (1986) 2823-2828
95. Tan Z.S., Seshadri S., Beiser A., Wilson P.W., Kiel D.P., Tocco M., D'Agostino R.B., and Wolf P.A. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch. Intern. Med. 163 9 (2003) 1053-1057
96. Trojano L., Inc A., Acanfora D., Picone C., Mecocci P., and Rengo F. Cognitive impairment: a key feature of congestive heart failure in the elderly. J. Neurol. 250 12 (2003) 1456-1463
97. Trollor J.N., Sachdev P.S., Haindl W., Brodaty H., Wen W., and Walker B.M. Regional cerebral blood flow deficits in mild Alzheimer's disease using high resolution single photon emission computerized tomography. Psychiatry Clin. Neurosci. 59 3 (2005) 280-290
98. van Exel E., de Craen A.J., Gussekloo J., Houx P., Bootsma-van der Wiel A., MacFarlane P.W., Blauw G.J., and Westendorp R.G. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann. Neurol. 51 6 (2002) 716-721
99. Vermeer S.E., Prins N.D., den Heijer T., Hofman A., Koudstaal P.J., and Breteler M.M. Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med. 348 13 (2003) 1215-1222
100. Vinkers D.J., Stek M.L., van der Mast R.C., de Craen A.J., Le Cessie S., Jolles J., Westendorp R.G., and Gussekloo J. Generalized atherosclerosis, cognitive decline, and depressive symptoms in old age. Neurology 65 1 (2005) 107-112
101. Weverling-Rijnsburger A.W., Jonkers I.J., van Exel E., Gussekloo J., and Westendorp R.G. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch. Intern. Med. 163 13 (2003) 1549-1554
102. Whitmer R.A., Sidney S., Selby J., Johnston S.C., and Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64 2 (2005) 277-281
103. Wilson P.W., Abbott R.D., and Castelli W.P. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 8 6 (1988) 737-741
104. Wolf H., Hensel A., Arendt T., Kivipelto M., Winblad B., and Gertz H.J. Serum lipids and hippocampal volume: the link to Alzheimer's disease?. Ann. Neurol. 56 5 (2004) 745-748
105. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57 10 (2000) 1439-1443
106. Wolozin B., Wang S.W., Li N.C., Lee A., Lee T.A., and Kazis L.E. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 5 (2007) 20
107. Yaffe K., Barrett-Connor E., Lin F., and Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch. Neurol. 59 3 (2002) 378-384
108. Zandi P.P., Sparks D.L., Khachaturian A.S., Tschanz J., Norton M., Steinberg M., Welsh-Bohmer K.A., and Breitner J.C. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch. Gen. Psychiatry 62 2 (2005) 217-224